Thursday, June 28, 2018

Level Brands, Inc, yesterday announced a seven-year licensing agreement with Boston Therapeutics, Inc., under the terms of the agreement, Boston Therapeutics is licensing the kathy ireland® Health & Wellness brand to market its popular diabetes supplement, Sugardown®. Boston Therapeutics will pay Level Brands an initial marketing fee of $850,000 to produce intellectual property to support the marketing efforts of the newest product to be branded under kathy ireland® Health & Wellness.

In the U.S., more than 100 million adults are now living with diabetes or prediabetes, according to a report released by the Centers for Disease Control (CDC) in July 2017. Sugardown® has been shown in clinical studies to help reduce post-meal elevation of blood sugar levels by up to 60% using galactomannans, a group of complex polysaccharides derived from plants that have been shown to possess significant activity in moderating post-meal blood glucose levels.

Boston Therapeutics will pay Level Brands an initial marketing fee of $850,000, paid pursuant to a $450,000 promissory note and $400,000 of Boston Therapeutics’ common stock. Level Brands will also earn royalties on gross sales using the licensed mark of 5% of the first $10 million in sales; 7.5% of sales between $10 million and $50 million; and 10% on sales exceeding $50 million.

Level Brands is a licensing, marketing and branding management company, headquartered in Charlotte, North Carolina. In November 2017, it became the seventh Regulation A+ IPO to complete and the second to list and trade on the NYSE American Exchange. Level Brands creates bold, unconventional and socially responsible branding for leading businesses. With a focus on consumer products marketing beauty, fashion and entertainment, Level Brands designs companies that disrupts industries to redefine leaders. Level Brands offers diverse industry portfolio:

kathy ireland® Health & Wellness

Beauty & Pin-Ups

Ireland Men One (IM1)

Encore Endeavor One (EE1)

Boston Therapeutics:

Boston Therapeutics, Inc. (BTI) is an innovator of novel therapies and diagnostics for unmet medical needs. Headquartered in Boston, MA, BTI has various operating centers worldwide including China supported by an experienced team of scientists, clinicians, regulatory affairs and business specialist. The main area of development that BTI has dedicated its efforts is Metabolic Syndrome. BTI aims to launch in the coming 3 years 2-3 preventive and therapeutic products of enhanced efficacy to provide better patient care, target major markets including US and China where Metabolic Syndrome is preponderant, its social burden significant and the unmet medical challenges the greatest.

Sugardown:

Sugardown®, a chewable pre-meal dietary supplement for glycemic health, has been shown in published clinical studies to help reduce post-meal elevation of blood sugar levels by up to 60% using a patented formulation of galactomannans, a group of complex polysaccharides derived from plants that have been shown to possess significant activity in moderating post-meal blood glucose levels and sugar digestion related enzymes.